GALAS Modeling Methodology Applications In The Prediction Of Drug Metabolism Related Properties
Poster Feb 21, 2017
Remigijus Didziapetris, Justas Dapkunas, Andrius Sazonovas and Pranas Japertas
Every model, no matter what data, descriptors, or modeling techniques used to build it, has a certain applicability domain, beyond which the quality of predictions becomes highly questionable. This reality is one of the fundamental issues concerning the effective use of third-party predictive algorithms in industry. The simple reason for this is that literature based training sets rarely cover the specific part of the chemical space that ‘in-house’ projects are focused on. Discrepancies between ‘in-house’ experimental protocols and methods used to measure properties for compounds in publicly available sources further affect the quality of resulting in silico predictions. Therefore the need has long existed for a method that would allow any company to effectively assess the Applicability Domain of any third-party model and to tailor it to its specific needs using proprietary ‘in-house’ data.
Addressing the aforementioned issue, a GALAS (Global, Adjusted Locally According to Similarity) model concept has been developed providing a novel solution to this problem.
Assessment of Oral LISPRO Treatment in Ameliorating Amyloid and Tau Pathology in Transgenic Alzheimer’s Mice ModelPoster
Ionic co-crystals of lithium salicylate with organic proline (LISPRO) showed better safety and pharmacokinetic profile of lithium in plasma and brain of wild-type and transgenic Alzheimer mice model compared to lithium salts.READ MORE
Determination of the Fat Content Profile of different Chocolate Products using an Automated Workflow for the Generation of Fatty Acid Methyl Esters (FAME)Poster
The method allows for automated determination of total fat content and quantitative analysis of saturated and unsaturated cis- and trans- fatty acids of different chocolate products.READ MORE
CiPA Phase 2 Study: validation of an automated microelectrode array (MEA) assay of hiPSC-derived cardiomyocyte electrophysiology for cardiac safety evaluationPoster
These results support the use of hSC-CM and MEA technology for preclinical assessment of proarrhythmic risk within the proposed CiPA paradigm, and, more generally, demonstrate that automation of the CM-MEA assay can achieve high reliability and throughput for cardiac risk assessment in vitro.READ MORE